SURVYR

PFE

Pfizer Inc.
$29.80
+$0.01 (0.03%)Oct 27 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-7%+2%+12%+22%+32%Oct 2025Oct 2026Apr 202652w high $30.4452w low $23.62
PFESPY
Wall St. Highest PT $36.00 (+20.8%) Wall St. Avg PT $29.26 (-1.8%)
$23$26$30$33$37POC $24Hi $36Avg $29
Underwater Drawdown %Max DD -15.7%Current -2.0%
0.0%-15.7%
Relative Strength vs SPY+15.2% vs SPYOutperforming
+27%0%-27%
1W
−$0.31 (1.03%)
1M
+$1.13 (3.94%)
3M
+$4.55 (18.02%)
6M
+$4.20 (16.40%)
YTD
+$6.12 (25.86%)
1Y
+$6.65 (28.74%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
26 analysts · mean score 2.50
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$29.80
Average target$29.26
−$0.54 (−1.8%) downsideaverage target vs current price
CurrentAverageMedian
Low$25.00
Median$28.50
High$36.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$171.2B
P/E (last 12 months)39.5
P/E (next 12 months, estimated)10.4
52-week range$23.62 – $30.44
Revenue growth (latest quarter vs a year ago)+2.6%
Dividend yield5.73%
Analyst consensusBuy (26)
Average analyst price target$29.26 (-2%)

What they do

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand.

Healthcare · Drug Manufacturers - General
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
56th percentile in sector
B-
12-1 return: +23.8%
Percentile within its GICS sector across the S&P 1500.
Growth
20th percentile in sector
D
Revenue growth (YoY): +2.6%
Percentile within its GICS sector across the S&P 1500.
Value
86th percentile in sector
A-
Forward E/P: 9.8% · EBITDA/EV: 11.5%
Percentile within its GICS sector across the S&P 1500.
Profitability
40th percentile in sector
C
Profit margin: +6.8% · Return on equity: +5.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 181 of 499 · 12-month momentum 19.5%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

PFE earningsNext report in 6 days
Next report · quarter Sep 2026
Tue Nov 3, 2026Before the open
EPS consensus$0.73
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 4, 2026$0.77est $0.68+12.9%Above estimates
May 5, 2026$0.75est $0.72+3.9%Above estimates
Feb 3, 2026$0.66est $0.57+16.2%Above estimates
Nov 4, 2025$0.87est $0.63+37.4%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-26 18:41:38 ET
24-1025-0225-0425-0825-1126-0226-0526-080.001.06
EstimateActual (beat)Actual (miss)

News & catalysts

More news
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
Nasdaq · 12h ago
3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist
Motley Fool · 17h ago
Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem
Nasdaq · Oct 24
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
24/7 Wall St. · Oct 23
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
Nasdaq · Oct 22
Insider trades
Bourla Albert
Director, Chairman & CEO · 2026-08-12
Buy
$1.0M
Buckley Mortimer J
Director · 2026-08-05
Buy
$960.4K
Blaylock Ronald E
Director · 2026-08-05
Buy
$998.8K
Damico Jennifer B.
SVP & Controller · 2026-08-05
Sell
$83.3K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-26 18:41:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026